While there was no specific decrease in cell survival in bone marrow, the percentage of live cells dramatically decreased with the TAK-659 treatment in the spleens and tumors of LMP2A/MYC mice, in both tumor cell transfer (Fig. 5B) and autochthonous (Fig. 5C) models. Here, MYC is linked to neoplasm.